Verbatim response from Perplexity
No telehealth services are confirmed to still safely offer compounded GLP-1s after the FDA’s March 2026 and June 2026 crackdowns, as major companies—including Ro, Hims & Hers, Good Life, and others—have either stopped offering them entirely or transitioned to FDA-approved alternatives like Wegovy, Zepbound, and Saxenda.
The FDA issued 30 warning letters in March 2026 and 25 additional warning letters in June 2026 to telehealth companies for falsely or misleadingly marketing compounded GLP-1 products, which the agency explicitly states are not FDA-approved and lack proven safety, efficacy, or consistent quality [1][2][3][4]. Most prominent healthcare providers now either prescribe compounded medications only when legally permitted (e.g., for allergies or unavailable dosages) or have eliminated compounded GLP-1 use altogether [2].
If you are seeking weight-loss treatment, the safest and most reliable options are currently:
- Wegovy (Novo Nordisk) – FDA-approved for chronic weight management [2]
- Zepbound (Eli Lilly) – FDA-approved for weight loss [2]
- Saxenda (Novo Nordisk) – FDA-approved, often used with generics [2]
For access to these, consult licensed telehealth platforms that now focus on approved medications, such as:
- Ro (now offers Wegovy and Zepbound)
- Hims & Hers (shifted to FDA-approved GLP-1s)
- Amble Health (mentioned in context, but verify current offerings) [5]
Always verify a company’s compliance status on the FDA’s Warning Letters page before signing up, as enforcement remains aggressive and ongoing [1][3].